Aclarion, Inc., previously known as Nocimed, Inc., has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering with the first sale yet to occur as of September 30, 2024. The filing, signed by James Carroll as an Authorized Representative on October 15, 2024, states that the company is based in Broomfield, Colorado, and has been incorporated for over five years in Delaware. The offering is exempt under Rule 506(b) and has a total offering amount of $1,000,000 USD, with the entire amount already sold. The minimum investment accepted from any outside investor is set at $200,000 USD. Aclarion has not allocated any of the gross proceeds from the offering for payments to its executive...Show More

Aclarion, Inc., previously known as Nocimed, Inc., has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering with the first sale yet to occur as of September 30, 2024. The filing, signed by James Carroll as an Authorized Representative on October 15, 2024, states that the company is based in Broomfield, Colorado, and has been incorporated for over five years in Delaware. The offering is exempt under Rule 506(b) and has a total offering amount of $1,000,000 USD, with the entire amount already sold. The minimum investment accepted from any outside investor is set at $200,000 USD. Aclarion has not allocated any of the gross proceeds from the offering for payments to its executive officers, directors, or promoters. The company's executive officers and directors, including Brent Ness, Stephen Deitsch, David Neal, Scott Breidbart, Jeffrey Thramann, William Wesemann, Amanda Williams, and John Lorbiecki, are listed in the filing. The issuer has claimed that the offering will not last more than one year and is not being made in connection with a business combination transaction.